医薬品医療機器レギュラトリーサイエンス
Online ISSN : 2436-6226
Print ISSN : 1884-6076
投稿 原著
複数種の液体クロマトグラフ質量分析計を用いたモデル核酸医薬品の分析データの比較
廣瀬 賢治吉田 徳幸寺崎 真樹瀬崎 浩史唐澤 薫岩崎 了教高原 健太郎滝口 直美関口 光明南海 浩一斎藤 恵美佐藤 秀昭大澤 昂志山口 卓男伊藤 浩介川上 純司小比賀 聡井上 貴雄
著者情報
ジャーナル フリー

2023 年 54 巻 5 号 p. 439-454

詳細
抄録

In evaluating the quality of oligonucleotide therapeutics, it is necessary to pay close attention to the presence of oligonucleotide impurities. As an analysis method, LC/MS, combining liquid chromatography (LC) and mass spectrometry (MS), is generally used for quality assessment. However, since the physicochemical properties of active pharmaceutical ingredient (API)-derived impurities are likely to be similar to those of the API, there are technical limitations on their separation and purification. Therefore, it is important to be aware of such limitations and to understand the capabilities of the analytical techniques used in evaluating the quality of oligonucleotide therapeutics with due consideration of the characteristics of the oligonucleotides and their manufacturing processes.

In order to achieve this, we analyzed model oligonucleotides using several different types of commercial liquid chromatograph-mass spectrometers (LC-MS). We investigated the LC separation of impurities from the parent oligonucleotide, the relative quantification of impurities, the characterization of the parent oligonucleotide, and the identification of impurities. In the LC separation of the impurities from the parent oligonucleotide, none of the LC-MS analyses achieved complete separation (Rs > 1.5) of all the major impurities. However, almost complete separations were observed between the parent oligonucleotide and three or more nucleotide-deleted oligonucleotide impurities. The relative quantification of impurities was not consistent among the LC-MS instruments tested here, and inconsistent ion suppressions or enhancements were observed. For the characterization of the parent oligonucleotide, the accuracy of deconvoluted mass was demonstrated to be within 3 ppm for all LC-MS analyses, and MS/MS sequence analysis showed 100% coverage in more than half of the cases. For the structural estimation of impurities, the mass accuracy was within 2 ppm for all LC-MS analyses when impurities were spiked at 0.1% or more, and the MS/MS sequence coverage was 76% or more when the spiked amounts of impurities were 1% or more. These results indicate that generally used LC/MS methods could provide reliable information for estimating the composition of impurities present at a level of 1% or more.

著者関連情報
© 2023 一般財団法人 医薬品医療機器レギュラトリーサイエンス財団
前の記事 次の記事
feedback
Top